{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:45:11Z","timestamp":1783338311556,"version":"3.54.6"},"reference-count":19,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,4,8]]},"DOI":"10.2967\/jnumed.124.269031","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:00:35Z","timestamp":1747940435000},"page":"jnumed.124.269031","source":"Crossref","is-referenced-by-count":3,"title":["[<sup>18<\/sup>F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study"],"prefix":"10.2967","author":[{"given":"David L.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Karfis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Mileva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunak","family":"Navalkissoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopinath","family":"Gnanasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Roach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Flamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn E.","family":"Caplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Toumpanakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"2025052212001054000_jnumed.124.269031v1.1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0589"},{"key":"2025052212001054000_jnumed.124.269031v1.2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","article-title":"Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score","volume":"128","author":"Chan","year":"2023","journal-title":"Br J Cancer."},{"key":"2025052212001054000_jnumed.124.269031v1.3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/RLU.0000000000001332","article-title":"Metabolic tumor volume and total lesion glycolysis in PET\/CT correlate with the pathological findings of colorectal cancer and allow its accurate staging","volume":"41","author":"Suzuki","year":"2016","journal-title":"Clin Nucl Med."},{"key":"2025052212001054000_jnumed.124.269031v1.4","doi-asserted-by":"crossref","unstructured":"Chardin D Paquet M Schiappa R . Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. J Immunother Cancer. 2020;8:e000645. ]","DOI":"10.1136\/jitc-2020-000645"},{"key":"2025052212001054000_jnumed.124.269031v1.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.244798"},{"key":"2025052212001054000_jnumed.124.269031v1.6","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1159\/000504673","article-title":"High metabolic tumour volume on 18-fluorodeoxyglucose positron emission tomography predicts poor survival from neuroendocrine neoplasms","volume":"110","author":"Chan","year":"2020","journal-title":"Neuroendocrinology."},{"key":"2025052212001054000_jnumed.124.269031v1.7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RLU.0000000000003937","article-title":"The combined interpretation of 68Ga-DOTATATE PET\/CT and 18F-FDG PET\/CT in metastatic gastroenteropancreatic neuroendocrine tumors: a classification system with prognostic impact","volume":"47","author":"Hayes","year":"2022","journal-title":"Clin Nucl Med."},{"key":"2025052212001054000_jnumed.124.269031v1.8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.18632\/oncotarget.27460","article-title":"Prognostic value of a three-scale grading system based on combining molecular imaging with 68Ga-DOTATATE and 18F-FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias","volume":"11","author":"Karfis","year":"2020","journal-title":"Oncotarget."},{"key":"2025052212001054000_jnumed.124.269031v1.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"},{"key":"2025052212001054000_jnumed.124.269031v1.10","doi-asserted-by":"crossref","unstructured":"Weber M Telli T Kersting D Seifert R . Prognostic implications of PET-derived tumor volume and uptake in patients with neuroendocrine tumors. Cancers (Basel). 2023;15:3581.]","DOI":"10.3390\/cancers15143581"},{"key":"2025052212001054000_jnumed.124.269031v1.11","doi-asserted-by":"crossref","unstructured":"Mapelli P Partelli S Salgarello M . Dual tracer 68Ga-DOTATOC and 18F-FDG PET improve preoperative evaluation of aggressiveness in resectable pancreatic neuroendocrine neoplasms. Diagnostics (Basel). 2021;11:192. ]","DOI":"10.3390\/diagnostics11020192"},{"key":"2025052212001054000_jnumed.124.269031v1.12","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1053\/j.gastro.2017.11.008","article-title":"Prognostic utility of total 68Ga-DOTATATE-avid tumor volume in patients with neuroendocrine tumors","volume":"154","author":"Tirosh","year":"2018","journal-title":"Gastroenterology."},{"key":"2025052212001054000_jnumed.124.269031v1.13","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.2967\/jnumed.120.258392","article-title":"Semiautomatic tumor delineation for evaluation of 64Cu-DOTATATE PET\/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume","volume":"62","author":"Carlsen","year":"2021","journal-title":"J Nucl Med."},{"key":"2025052212001054000_jnumed.124.269031v1.14","doi-asserted-by":"crossref","unstructured":"Alevroudis E Spei ME Chatziioannou SN . Clinical utility of 18F-FDG PET in neuroendocrine tumors prior to peptide receptor radionuclide therapy: a systematic review and meta-analysis. Cancers (Basel). 2021;13:1813. ]","DOI":"10.3390\/cancers13081813"},{"key":"2025052212001054000_jnumed.124.269031v1.15","doi-asserted-by":"crossref","first-page":"e560","DOI":"10.1097\/MPA.0000000000002336","article-title":"Metabolic tumor volume on 18-fluorodeoxyglucose positron emission tomography as a prognostic marker of survival in patients with locally advanced or metastatic neuroendocrine neoplasms treated with 177lutetium-DOTA-octreotate peptide receptor radionuclide therapy","volume":"53","author":"De Silva","year":"2024","journal-title":"Pancreas."},{"key":"2025052212001054000_jnumed.124.269031v1.16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000480239","article-title":"18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation","volume":"106","author":"Bucau","year":"2018","journal-title":"Neuroendocrinology."},{"key":"2025052212001054000_jnumed.124.269031v1.17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13550-022-00901-2","article-title":"A convolutional neural network for total tumor segmentation in [64Cu]Cu-DOTATATE PET\/CT of patients with neuroendocrine neoplasms","volume":"12","author":"Carlsen","year":"2022","journal-title":"EJNMMI Res."},{"key":"2025052212001054000_jnumed.124.269031v1.18","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1210\/jc.2016-3865","article-title":"Utility of FDG-PET imaging for risk stratification of pancreatic neuroendocrine tumors in MEN1","volume":"102","author":"Kornaczewski Jackson","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"2025052212001054000_jnumed.124.269031v1.19","doi-asserted-by":"crossref","first-page":"e13359","DOI":"10.1111\/jne.13359","article-title":"Use and perceived utility of [18F]FDG PET\/CT in neuroendocrine neoplasms: a consensus report from the European Neuroendocrine Tumor Society (ENETS) advisory board meeting 2022","volume":"36","author":"Ambrosini","year":"2024","journal-title":"J Neuroendocrinol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.269031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:00:39Z","timestamp":1747940439000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.269031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":19,"alternative-id":["10.2967\/jnumed.124.269031"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.269031","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]}}}